keyword
https://read.qxmd.com/read/38536193/-complications-of-intravesical-bcg-therapy
#1
JOURNAL ARTICLE
Aresh Farokhnia, Silvana K Rampini, Micha Gundelfinger
BCG instillations are considered to be the standard of care therapy for superficial urothelial bladder carcinoma. Although serious adverse events are uncommon, the presence of high fever for at least two days in conjunction with systemic and/or local organ manifestations (except for urogenital symptoms), with the exclusion of other causes, suffice for the diagnosis of a disseminated BCG infection. Microbiologic detection of the pathogen is not necessary for diagnosis, as the detection of granuloma is more often successful and sufficient...
February 2024: Praxis
https://read.qxmd.com/read/38517278/factors-associated-with-onabotulinum-toxin-a-discontinuation-in-a-diverse-urban-population
#2
JOURNAL ARTICLE
Tyler Bergeron, Arshia Aalami Harandi, Mariel Liebeskind, Nitya Abraham
IMPORTANCE: Although overactive bladder (OAB) is a common condition, affecting 16% of Americans, few patients continue on to advanced therapies. Furthermore, procedural therapies like intravesical onabotulinum toxin-A (BTX-A), which require ongoing repeat treatments, have discontinuation rates ranging from 25% to 51%. OBJECTIVES: This study sought to investigate factors associated with dis-continuation of BTX-A injections for idiopathic OAB among a diverse urban population...
March 21, 2024: Urogynecology (Phila)
https://read.qxmd.com/read/38512511/treatment-patterns-and-prognosis-in-patients-with-bacillus-calmette-gu%C3%A3-rin-exposed-high-risk-non-muscle-invasive-bladder-cancer-a-real-world-data-analysis
#3
JOURNAL ARTICLE
Nobutaka Nishimura, Makito Miyake, Kota Iida, Tatsuki Miyamoto, Ryotaro Tomida, Kazuyuki Numakura, Junichi Inokuchi, Takahiro Yoneyama, Eijiro Okajima, Shugo Yajima, Hitoshi Masuda, Naoki Terada, Rikiya Taoka, Takashi Kobayashi, Takahiro Kojima, Yoshiyuki Matsui, Naotaka Nishiyama, Hiroshi Kitamura, Hiroyuki Nishiyama, Kiyohide Fujimoto
PURPOSE: The International Bladder Cancer Group designated the subgroup that is resistant to Bacillus Calmette-Guérin (BCG) but does not meet the criteria for BCG-unresponsive NMIBC as "BCG-exposed high-risk NMIBC" to guide optimal trial design. We aimed to investigate the treatment patterns and prognoses of patients with BCG-exposed NMIBC. METHODS: We conducted a retrospective chart review of 3283 patients who received intravesical BCG therapy for NMIBC at 14 participating institutions between January 2000 and December 2019...
March 21, 2024: World Journal of Urology
https://read.qxmd.com/read/38508149/the-efficacy-and-safety-of-hyperthermia-intravesical-chemotherapy-in-the-treatment-non-muscle-invasive-bladder-cancer-a-meta-analysis
#4
Huanglin Duan, Zanxuan Deng, Junrong Zou, Guoxi Zhang, Xiaofeng Zou, Tianpeng Xie
Background:The current treatment of non-muscle-invasive bladder cancer is suboptimal. However, in recent years, hyperthermia intravesical chemotherapy has emerged as a more effective alternative to conventional bladder perfusion. This novel treatment approach appears to have a similar therapeutic effect as BCG perfusion. Objective: This study aims to evaluate the safety and effectiveness of hyperthermia intravesical chemotherapy compared to conventional bladder perfusion chemotherapy for non-muscle-invasive bladder cancer...
March 20, 2024: Urologia Internationalis
https://read.qxmd.com/read/38506306/disseminated-bcgitis-after-intravesical-bacillus-calmette-gu%C3%A3-rin-therapy-in-a-patient-with-bladder-cancer
#5
JOURNAL ARTICLE
Marcin Skowroński, Paweł Halicki, Anna Halicka
No abstract text is available yet for this article.
March 20, 2024: Polish Archives of Internal Medicine
https://read.qxmd.com/read/38502039/patterns-of-treatment-of-high-risk-bcg-unresponsive-non-muscle-invasive-bladder-cancer-nmibc-patients-among-arab-urologists
#6
JOURNAL ARTICLE
Mohamad Moussa, Mohamad Abou Chakra, Neal D Shore, Athanasios Papatsoris, Yasser Farahat, Michael A O'Donnell
PURPOSE: To understand the treatment plans suggested for BCG-unresponsive non-muscle invasive disease (NMIBC) patients in the Arab countries and therapeutic decisions applied for BCG-naive patients during BCG shortage time. METHODS: A 10-minute online survey was distributed through the Arab Association of Urology (AAU) office to urologists in the Arab countries who treat patients with NMIBC. RESULTS: One hundred six urologists responded to the survey...
March 19, 2024: Archivio Italiano di Urologia, Andrologia
https://read.qxmd.com/read/38499004/a-selective-tumor-penetrating-strategy-via-unidirectional-direct-transfer-for-intravesical-therapy-of-bladder-cancer
#7
JOURNAL ARTICLE
Xiaowen Qin, Heng Wang, Wentao Xu, Bin Zheng, Haibao Zhang, Qi Zhang, Yang Liu, Zhenghong Liu, Li Sun, Yixuan Mou, Cenchao Yao, Wei Zheng, Yiyang Chen, Chenkai Wang, Xuanyi Zhou, Youqing Shen, Pu Zhang, Dahong Zhang
A selective tumor-penetrating strategy generally exploits tumor-targeted ligands to modify drugs so that the conjugate preferentially enters tumors and subsequently undergoes transcellular transport to penetrate tumors. However, this process shields ligands from their corresponding targets on the cell surface, possibly inducing an off-target effect during drug penetration at the tumor-normal interface. Herein, we first describe a selective tumor-penetrating drug (R11-phalloidin conjugates) for intravesical therapy of bladder cancer...
March 18, 2024: Journal of Medicinal Chemistry
https://read.qxmd.com/read/38497135/assessment-of-symptomatic-response-to-intravesical-alkalinized-lidocaine-bupivacaine-heparin-and-steroids-in-patients-with-bladder-pain-syndrome
#8
JOURNAL ARTICLE
Ravikant Mahant, Fanindra Singh Solanki, Chandan Tiwari, Ankush Lokhande, Deepti B Sharma, Dhananjaya Sharma
Bladder Pain Syndrome (BPS) is a puzzling and complicated disorder. 12 such patients, with a mean age 48.3 years, were treated with weekly intravesical instillation of admixture of alkalinized lidocaine, bupivacaine, heparin and steroids for six weeks. Evaluating the benefits of this therapy, patients experienced 82.2% & 90.9% relief at 3rd & 6th week of instillation. After completion of six cycles of therapy, patients experienced 68.7% & 65.3% relief at 3rd & 6th month follow up, concluding the early and long term relief of BPS...
March 18, 2024: Tropical Doctor
https://read.qxmd.com/read/38491799/cost-effectiveness-analysis-of-different-treatment-modalities-in-bcg-unresponsive-nmibc
#9
JOURNAL ARTICLE
Constantin Rieger, Jörg Schlüchtermann, Enno Storz, Lucas Kastner, David Pfister, Axel Heidenreich
OBJECTIVE: Radical cystectomy (RC) is the standard of care (SOC) in BCG-unresponsive NMIBC and is associated with a significant health-related quality-of-life burden. Recently, promising results have been published on Gemcitabine/Docetaxel, Pembrolizumab, and Hyperthermic Intravesical Chemotherapy (HIVEC) as salvage therapy options trying to increase the rate of bladder preservation. Here, we performed a Cost-Effectiveness-Analysis of those treatment modalities. PATIENTS AND METHODS: We developed a Markov model from a payer's perspective drawing on clinical data of single-arm trials testing intravesical gemcitabine/docetaxel and pembrolizumab in BCG-unresponsive NMIBC, as well as clinical data from patients receiving hyperthermic intravesical chemotherapy HIVEC (n = 29) as intravesical salvage chemotherapy at our uro-oncological centre in Cologne...
March 16, 2024: BJU International
https://read.qxmd.com/read/38481675/patient-experience-of-bladder-cancer-a-data-linkage-study
#10
JOURNAL ARTICLE
Snehadhar Shah, Jonathan Ince, Roger Kockelbergh
INTRODUCTION: Bladder cancer is one of the most common cancers worldwide and can be managed with a range of approaches, including conservative, medical and surgical therapies. Treatment may be associated with considerable morbidity, but despite this, little data exist to reflect patients' subsequent experience. This study aims to evaluate patients' experiences of bladder cancer care by linking data from a national cancer experience survey with data routinely collected from National Health Service (NHS) sources...
March 2024: BJUI compass
https://read.qxmd.com/read/38466867/efficacy-and-tolerability-of-bacillus-calmette-gu%C3%A3-rin-strain-russia-for-the-treatment-of-non-muscle-invasive-bladder-cancer-analysis-of-a-prospective-registry
#11
JOURNAL ARTICLE
Sarah Flury-Sutter, Frederick Heuzeroth, Emilio Arbelaez, Lukas Bubendorf, Heike Püschel, Stefanie Hayoz, Cyrill A Rentsch
INTRODUCTION: Little is known about the efficacy and tolerability of intravesical bacillus Calmette-Guérin (BCG) strain Russia for treatment of non-muscle-invasive bladder cancer (NMIBC) in a middle- European population. METHODS: A prospective collection of outcomes of 101 BCG-naive patients with urothelial bladder carcinoma was carried out between January 2013 and October 2023 at the University Hospital Basel, Basel, Switzerland. Patients underwent BCG (ONCO-BCGSIIL, Serum Institute of India, Pune, India) induction and a maximum of three maintenance cycles within one year...
March 1, 2024: Canadian Urological Association Journal
https://read.qxmd.com/read/38466144/targeted-delivery-of-catalase-and-photosensitizer-ce6-by-a-tumor-specific-aptamer-is-effective-against-bladder-cancer-in-vivo
#12
JOURNAL ARTICLE
Yang Zhang, Ru Jia, Xiaoyi Wang, Yixuan Zhang, Jinhui Wu, Quansheng Yu, Qiang Lv, Chao Yan, Pengchao Li
Photodynamic therapy (PDT) is often applied in a clinical setting to treat bladder cancer. However, current photosensitizers report drawbacks such as low efficacy, low selectivity, and numerous side effects, which have limited the clinical values of PDT for bladder cancer. Previously, we developed the first bladder cancer-specific aptamer that can selectively bind to and be internalized by bladder tumor cells versus normal uroepithelium cells. Here, we use an aptamer-based drug delivery system to deliver photosensitizer chlorine e6 (Ce6) into bladder tumor cells...
March 11, 2024: Molecular Pharmaceutics
https://read.qxmd.com/read/38447202/mucoadhesive-thiolated-hyaluronic-acid-pluronic-f127-nanogel-formation-via-thiol-maleimide-click-reaction-for-intravesical-drug-delivery
#13
JOURNAL ARTICLE
Fayang Li, Xianhuang Chen, Yuanqiao He, Zhiping Peng
The development of nanocarriers to prolong the residence time and enhance the permeability of chemotherapeutic drugs on bladder mucosa is important in the postsurgery treatment of superficial bladder cancers (BCs). Here, the mucoadhesive HA-SH/PF127 nanogels composed of a temperature-sensitive Pluronic F127 (PF127) core and thiolated hyaluronic acid (HA-SH) shell were prepared by the emulsification/solvent evaporation method. The nanogels were constructed through the thiol-maleimide click reaction in the HA-SH aqueous side of the oil-water interface and self-oxidized cross-linking thiols between HA-SH...
March 6, 2024: ACS Applied Bio Materials
https://read.qxmd.com/read/38440709/successful-treatment-with-low-dose-oral-steroids-for-contracted-bladder-after-intravesical-instillation-of-bacillus-calmette-gu%C3%A3-rin
#14
Akinobu Katami, Takamitsu Inoue, Hiromichi Sakurai, Mizuki Onozawa, Shin-Ichi Hisasue, Koji Kawai, Jun Miyazaki
INTRODUCTION: Contracted bladder is a rare adverse effect of intravesical Bacillus Calmette-Guérin instillation, with an incidence of 0.2-3.3%. This report aimed to present a case of contracted bladder successfully treated with a low-dose oral steroid. CASE PRESENTATION: A 78-year-old man underwent a third transurethral resection of a bladder tumor. The pathological diagnosis was urothelial carcinoma in situ. After the fifth instillation of the second-line induction therapy of Bacillus Calmette-Guérin, the patient discontinued treatment because of increased urinary frequency and a continuous mean voiding volume of 80 mL...
March 2024: IJU case reports
https://read.qxmd.com/read/38439550/intravesical-sequential-gemcitabine-docetaxel-for-non-muscle-invasive-bladder-cancer-tips-and-tricks-for-better-efficacy-and-tolerability
#15
JOURNAL ARTICLE
Mohamad Abou Chakra, Mohamad Moussa, Michael A O'Donnell
No abstract text is available yet for this article.
March 4, 2024: Journal of Chemotherapy
https://read.qxmd.com/read/38430858/recurrent-bacteriuria-as-a-prognosis-marker-in-the-adjuvant-treatment-of-non-muscle-invasive-bladder-cancer
#16
JOURNAL ARTICLE
Juliusz J Szczesniewski, Magaly T Márquez-Sánchez, Bárbara Padilla-Fernández, Luis Llanes-González, María F Lorenzo-Gómez
PURPOSE: Bacteriuria may affect the response to adjuvant therapy in non-muscle invasive bladder cancer (NMIBC). The main aim of this study was to examine the effect of recurrent bacteriuria (RB) on the prognosis of NMIBC in women receiving intravesical therapy. MATERIALS AND METHODS: We designed a prospective observational study from 2012 to 2019. We included women with bladder cancer treated with transurethral resection of the bladder (TURB) and adjuvant intravesical treatment...
February 1, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38423631/comparing-clinical-efficacy-of-different-bacillus-calmette-gu%C3%A3-rin-strains-in-patients-with-t1-high-grade-bladder-cancer
#17
JOURNAL ARTICLE
Ssu-Hung Yu, Ci-Yu Wang, Shian-Shiang Wang, Jian-Ri Li, Sheng-Chun Hung
BACKGROUND/AIM: This study aimed to compare the clinical efficacy of two different Bacillus Calmette-Guérin (BCG) strains, TICE strain (OncoTICE) and Connaught strain (ImmuCyst), as a first line intravesical instillation therapy in patients with T1 high grade bladder cancer. PATIENTS AND METHODS: Patients with newly diagnosed T1 high-grade bladder cancer who underwent transurethral resection of bladder tumor (TURBT) followed by intravesical instillation therapy were enrolled...
March 2024: Anticancer Research
https://read.qxmd.com/read/38392073/bcg-and-alternative-therapies-to-bcg-therapy-for-non-muscle-invasive-bladder-cancer
#18
REVIEW
Sarah Lidagoster, Reuben Ben-David, Benjamin De Leon, John P Sfakianos
Bladder cancer is a heterogeneous disease. Treatment decisions are mostly decided based on disease stage (non-muscle invasive or muscle invasive). Patients with muscle-invasive disease will be offered a radical treatment combined with systemic therapy, while in those with non-muscle-invasive disease, an attempt to resect the tumor endoscopically will usually be followed by different intravesical instillations. The goal of intravesical therapy is to decrease the recurrence and/or progression of the tumor. In the current landscape of bladder cancer treatment, BCG is given intravesically to induce an inflammatory response and recruit immune cells to attack the malignant cells and induce immune memory...
February 16, 2024: Current Oncology
https://read.qxmd.com/read/38391841/quality-of-life-and-treatment-modalities-in-patients-with-interstitial-cystitis-the-patients-perspective
#19
JOURNAL ARTICLE
Charlotte van Ginkel, Frank Martens, Mathilde Scholtes, John Heesakkers, Dick A W Janssen
BACKGROUND: Quality of life (QoL)-based outcomes are hardly incorporated into interstitial cystitis/bladder pain syndrome (IC/BPS) guidelines, because studies are limited and outdated. Therefore, guidelines might not reflect the current clinical situation accurately. Secondly, guidelines suggest using a multimodal approach for BPS/IC management, but data on the patient-perceived efficacy of these therapies are limited. The aim of this study is to investigate the perception of IC/BPS patients of their QoL, to determine which treatments they have received, and to examine how they evaluate the efficacy of these various (alternative) therapies...
February 13, 2024: Healthcare (Basel, Switzerland)
https://read.qxmd.com/read/38390786/shifts-in-patient-preference-of-third-line-overactive-bladder-therapy-after-introduction-of-the-implantable-tibial-nerve-stimulator
#20
JOURNAL ARTICLE
Anjali Kapur, Arshia Aalami Harandi, Jacob Hartman-Kenzler, Jason Kim
INTRODUCTION: Third-line therapies for overactive bladder (OAB) that are currently recommended include intravesical Onabotulinumtoxin-A injections (BTX-A), percutaneous tibial nerve stimulation (PTNS), and sacral neuromodulation (SNM). The implantable tibial nerve stimulator (ITNS) is a novel therapy that is now available to patients with OAB. OBJECTIVE: The objective of this study was to analyze shifts in patient preference of third-line therapies for OAB after introducing ITNS as an option among the previously established therapies for non-neurogenic OAB...
February 23, 2024: Neurourology and Urodynamics
keyword
keyword
21306
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.